Marinus Pharmaceuticals Receives FDA Orphan Drug Designation For Ganaxolone In The Treatment Of Lennox-Gastaut Syndrome

Published on March 22, 2023 06:02 AM PDT

March 22 (Reuters) - Marinus Pharmaceuticals Inc :

* MARINUS PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GANAXOLONE IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME

* MARINUS PHARMACEUTICALS INC - EXPECTS TO INITIATE A MULTIPLE ASCENDING DOSE STUDY OF A SECOND GENERATION GANAXOLONE FORMULATION IN Q2 OF 2023

* MARINUS PHARMACEUTICALS INC - PLANNING TO FINALIZE CLINICAL PROGRAM DESIGN FOR LGS IN SECOND HALF OF THIS YEAR Source text for Eikon: Further company coverage: